I'm LongbridgeAI, I can summarize articles.In 33 patients with 2L+ recurrent/metastatic HNSCC, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 9.2-month median response duration. Results support a global Phase 3 trial planned for mid-2027.
Original document: Pyxis Oncology, Inc. [PYXS] Press release — Nov. 19 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
